Faeth Therapeutics, Inc. (FTH): Capital Expenditures
$16.0K
Year ended 2025-12-31
$6.0K
Trailing 12 months to 2026-06-30
-63.2%
3-year compound annual growth
-57.9%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $16.0K | -89.0% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $146.0K | -18.9% | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | $180.0K | -43.9% | 2025-03-28, From 2023-01-01 |
| 2022-12-31 | $321.0K | -84.2% | 2024-02-29, From 2022-01-01 |
| 2021-12-31 | $2.03M | +68.0% | 2023-03-29, From 2021-01-01 |
| 2020-12-31 | $1.21M | n/a | 2022-03-15, From 2020-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | 2025-12-31 | $16.0K | -89.0% |
| Gain Therapeutics, Inc. (GANX) | 2024-12-31 | $22.5K | +46.5% |
| Moleculin Biotech, Inc. (MBRX) | 2025-12-31 | $0 | -100.0% |
| Immunic, Inc. (IMUX) | 2025-12-31 | $161.0K | -39.0% |
| Kiora Pharmaceuticals Inc (KPRX) | 2025-12-31 | $110.8K | n/m |
| Phio Pharmaceuticals Corp. (PHIO) | 2025-12-31 | $12.0K | n/m |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $1.0K | -91.7% |
| HCW Biologics Inc. (HCWB) | 2025-12-31 | $0 | -100.0% |
| Integrated Biopharma Inc (INBP) | 2025-06-30 | $191.0K | -65.5% |
Compare FTH, GANX, MBRX, IMUX side by side · Screen every company in Pharmaceutical Preparations ↗